Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections (EVAMICA)

Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units

The primary purpose is to improve and quicken the microbial diagnosis in severe infections, since only one third of the cases are documented by blood cultures and adequate anti-infective therapy in the 48 hours reduced mortality and morbidity.

Our hypothesis is that detection of microbial DNA in blood by real time PCR may increase the number of cases diagnosed for bacteraemia or fungemia and shorten the time to positive results, which will provide information for an adequate anti-infectious therapy.

Study Overview

• Status: Completed
• Conditions: Febrile Neutropenia; Severe Sepsis; Endocarditis
• Intervention / Treatment: Other: detection of microbial DNA in blood by blood culture; Other: Detection of microbial DNA in blood by SeptiFast®

Detailed Description

We will evaluate the advantage of adding the molecular test to the microbial investigations usually done (blood cultures and others) in cases of febrile neutropenia, suspicion of infective endocarditis and severe sepsis in intensive care units.

This is a prospective study conducted in 18 sites (7 in the Paris area and 11 all over France) which will enrolled about 2000 patients over 18 years. Sites are randomized for starting with a 6-month period performing the test or 6-month period without the test (control time with the standard of care).

Primary outcome are the number of patients with documented bacteraemia or fungemia. Secondary outcome are (1) the number of patients with an adequate anti-infective therapy and how long it happens after the diagnosis, (2) mortality, (3) new complicated infection, (4) number of investigations (microbial and non microbial) done for the etiological diagnosis, and global hospitalization costs.

The advantage of the new test will be evaluated per protocol and with an intend to treat analyses. We hypothesized that the new test will bring 15% more microbial diagnosis than the standard of care. Consequently, and according to the number of sites interested in the study, 166 to 2500 patients will be enrolled with 480 to 750 patients with febrile neutropenia, 1000 to 1500 patients with severe sepsis in Intensive Care Units (ICU). Patients with suspicion of infective endocarditis will be evaluated for the number of diagnosis of true endocarditis according to Duke Criteria, and the time to diagnosis.

Health economic evaluation will compare the costs of hospitalization, microbial investigations including the new test, other non clinical investigations and consequences on the organization.

• Study Type: Interventional
• Enrollment (Actual): 2000
• Phase: Phase 4

Contacts and Locations

Study Locations

• France
  • Créteil, France
    • CHU Henri Mondor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age≥ 18 years
• Written signed and dated inform consent
• First time with fever observed in a neutropenic patient
• Severe sepsis in a patient hospitalized in ICU
• Suspicion of infective endocarditis
• Microbial investigation from Monday to Friday

Exclusion Criteria:

• Not affiliated to Health Insurance (social security)
• Included in another interventional trial testing microbial DNA detection during the time "without Septifast®"
• Included in another clinical trial for which the clinician assumes that it will not be possible to prescribe an anti-infectious therapy adequately to microbial detection in the blood
• Patient previously included in the protocol
• Sepsis with a microbial diagnosis

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 2; Detection by blood culture	Other: detection of microbial DNA in blood by blood culture; A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
Experimental: 1; Test LightCycler SeptiFast® (Roche)	Other: Detection of microbial DNA in blood by SeptiFast®; The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps. Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of bacteraemia and of fungemia - overall - each condition	max Day 30

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of patients with adequate anti-infective therapy	at day 30
Adequate anti-infective therapy	at 24h, 48h, > 48h
Time between sampling for microbial investigation and positive results relevant for the diagnosis	between sampling for microbial investigation and positive results
Mortality	at Day 30
Sepsis chock, secondary infectious focus	at Day 30
For neutropenia cases, number of patients who evaluated with a clinical focus of infection	at day 30
Diagnosis of endocarditis	at Day 45
Number of non clinical investigations (microbial and non microbial)	at day 30
Length of hospital stay	at day 30

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborators: Hoffmann-La Roche
• Investigators: Principal Investigator: Emmanuelle CAMBAU, PH, Assistance Publique - Hôpitaux de Paris; Principal Investigator: René COURCOL, PH, CHRU Lille

Publications and helpful links

General Publications

• Cambau E, Durand-Zaleski I, Bretagne S, Brun-Buisson C, Cordonnier C, Duval X, Herwegh S, Pottecher J, Courcol R, Bastuji-Garin S; EVAMICA study team. Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial. Intensive Care Med. 2017 Nov;43(11):1613-1625. doi: 10.1007/s00134-017-4766-4. Epub 2017 Apr 3.

Study record dates

Study Major Dates

• Study Start: May 1, 2008
• Primary Completion (Actual): September 1, 2010
• Study Completion (Actual): September 1, 2010

Study Registration Dates

• First Submitted: July 2, 2008
• First Submitted That Met QC Criteria: July 2, 2008
• First Posted (Estimate): July 3, 2008

Study Record Updates

• Last Update Posted (Estimate): December 29, 2011
• Last Update Submitted That Met QC Criteria: December 26, 2011
• Last Verified: May 1, 2011

More Information

Terms related to this study

• Keywords: bacteria; fungi; real time PCR; adequate antimicrobial therapy; microbial DNA; microbial diagnosis
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Wounds and Injuries; Hematologic Diseases; Agranulocytosis; Leukopenia; Leukocyte Disorders; Body Temperature Changes; Heat Stress Disorders; Sepsis; Neutropenia; Hyperthermia; Fever; Endocarditis; Febrile Neutropenia
• Other Study ID Numbers: P070308